Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anopyxis klaineana extract is a botanical extract derived from the stem bark of the West African ethnomedicinal tree *Anopyxis klaineana*. It is primarily being investigated for its potential therapeutic applications as an antiparasitic agent against *Trypanosoma brucei*, the causative agent of African trypanosomiasis (sleeping sickness). In vitro and in silico studies have demonstrated that the extract and its active fractions (such as hexane, chloroform, and ethyl acetate) exhibit significant antitrypanosomal activity. The mechanism of action is believed to involve the inhibition of key parasite enzymes, specifically trypanothione reductase (TR) and uridine diphosphate galactose 4'-epimerase (TbGalE), which are essential for the parasite's survival. Additionally, the extract has shown potential anti-inflammatory, analgesic, and antidepressant-like properties in preclinical animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anopyxis klaineana extract.